Kim Min Seok, Nam Seonghee, Park Sang Jun, Lee Jeongwoo, Woo Se Joon
Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Data Research, Samil Pharm Co. LTD., Seoul, Korea.
J Korean Med Sci. 2025 Jul 7;40(26):e128. doi: 10.3346/jkms.2025.40.e128.
Updating the recent epidemiology of exudative age-related macular degeneration (AMD) is crucial for understanding the epidemiological trend of the disease, preparing healthcare strategies, and providing data for global comparisons. This study aimed to estimate the nationwide trend in prevalence and incidence of exudative AMD in Korea.
In this nationwide population-based study using the National Health Insurance Service data, patients who have registration code for exudative AMD and aged 40 years or older were extracted from 2013 to 2022. Cumulative prevalence from 2013 onwards, annual prevalence, and incidence was estimated per 10,000 people. We also calculated age-standardized estimates using the World Health Organization population proportions. Linear regression to test time trend was performed. The annual prevalence and incidence were predicted using time series analysis.
The crude cumulative prevalence of exudative AMD was 42.7 in 2022, with men having a higher prevalence than women (51.3 vs. 34.6). The annual prevalence rose from 10.7 in 2013 to 22.5 in 2022 (age-standardized, < 0.001). The incidence consistently increased from 2.8 in 2013 to 4.7 in 2022 (age-standardized, = 0.001), with higher incidence in men than in women. The prevalence and incidence of exudative AMD were higher in older age groups and showed a faster increase with advancing age. The predicted annual prevalence and incidence of exudative AMD in 2040 are 46.2 and 8.4, respectively. The crude cumulative number of patients was 127,044 in 2022 and is projected to reach 230,899 in 2030 and 374,282 in 2040.
The prevalence and incidence of exudative AMD in Korea has been increased annually, especially in the elderly group. With the Korean and global population aging, there will be a growing burden from visual impairment and medical expenses associated with exudative AMD.
更新渗出性年龄相关性黄斑变性(AMD)的近期流行病学对于了解该疾病的流行病学趋势、制定医疗保健策略以及提供全球比较数据至关重要。本研究旨在估计韩国全国范围内渗出性AMD的患病率和发病率趋势。
在这项基于全国人群的研究中,使用了国民健康保险服务数据,从2013年至2022年提取了有渗出性AMD登记代码且年龄在40岁及以上的患者。按每10000人估计从2013年起的累积患病率、年患病率和发病率。我们还使用世界卫生组织的人口比例计算了年龄标准化估计值。进行线性回归以检验时间趋势。使用时间序列分析预测年患病率和发病率。
2022年渗出性AMD的粗累积患病率为42.7,男性患病率高于女性(51.3对34.6)。年患病率从2013年的10.7上升至2022年的22.5(年龄标准化,<0.001)。发病率从2013年的2.8持续增加至2022年的4.7(年龄标准化,=0.001),男性发病率高于女性。渗出性AMD的患病率和发病率在老年人群中更高,且随着年龄增长上升更快。预计2040年渗出性AMD的年患病率和发病率分别为46.2和8.4。2022年患者的粗累积人数为127044,预计到2030年将达到230899,到2040年将达到374282。
韩国渗出性AMD的患病率和发病率逐年上升,尤其是在老年人群中。随着韩国和全球人口老龄化,与渗出性AMD相关的视力损害和医疗费用负担将不断增加。